Evaluation of pancreatic stent and/or suppository indomethacin efficacy in post ERCP pancreatitis prophylaxis: a single center experience

Authors : Çağdaş ERDOĞAN, İbrahim Ethem GÜVEN, Batuhan BAŞPINAR, Zeki Mesut Yalın KILIÇ

Pages : 374-379

Doi:10.32322/jhsm.1197804

View : 21 | Download : 13

Publication Date : 2023-03-27

Article Type : Research Paper

Abstract :Aim: Post-endoscopic retrograde cholangiopancreatography insert ignore into journalissuearticles values(ERCP); pancreatitis insert ignore into journalissuearticles values(PEP); is a serious complication of ERCP. In this study, we aimed to compare the use of rectal indomethacin, pancreatic stenting or both techniques for prevention of PEP. Material and Method: Patients who underwent ERCP for the first time due to choledocholithiasis between January 2022 and June 2022 were retrospectively reviewed. The clinical findings, demographics, laboratory records, endoscopic intervention characteristics, whether rectal indomethacin was applied before the procedure, whether pancreatic stent was placed or not were evaluated. Results: A total of 367 patients who underwent ERCP for the first time were included in the study. The mean age was 61 insert ignore into journalissuearticles values(28-92); years and 53.4% were female. In 124 insert ignore into journalissuearticles values(33.8%); patients, involuntary guide-wire insertion into the pancreatic duct occurred during canulation. Pancreatic stent was placed in 82 insert ignore into journalissuearticles values(22.3%); of the patients. Rectal indomethacin was administered to 288 patients insert ignore into journalissuearticles values(78.5%);, while indomethacin could not be administered in 79 patients insert ignore into journalissuearticles values(21.5%);, because they did not give consent. When patients with involuntarily pancreatic canulation were evaluated, the rate of PEP was 3.6% in the stented group, while it was 15.3% in the stent-free group insert ignore into journalissuearticles values(p<0001);. The incidence of PEP was 20.3% in 79 patients who could not be administered rectal indomethacin, while this rate was 3.1% in those who received rectal indomethacin insert ignore into journalissuearticles values(p<0001);. Conclusion: The first and most important way to prevent PEP is to avoid unnecessary ERCPs. Rectal indomethacin administration reduces the risk of PEP. All patients with involuntary wires in the pancreatic duct, should be evaluated for pancreatic stent placement.
Keywords : Post ERCP pancreatitis, rectal indomethacin, pancreatic stent, prophlaxis